Research conducted by global partnerships for research and development of antibiotics, non -profit health organizations, revealed that a significant number of infections resistant to multiple drugs in low and medium income countries, including India, are not treated reasonably due to large gaps in the approach. | Photo Credit: Reuters
Only 7.8% of patients with infections resistant to drugs in India were given a suitable antibiotic, and a study of eight countries published in the LANTITIOUS Diseases magazine was revealed. Lack of access to appropriate treatment of such serious infections increases morbidity and mortality, in addition to increasing health care costs and prolonging hospitalization.
Research conducted by global partnerships for research and development of antibiotics (GARDP), non -profit health organization, revealed that a significant number of infections resistant to multiple drugs in countries with low and medium income (LMIC), including India, are not treated due to large gaps.
The study dealt with antibiotics available to treat almost 1.5 million cases of gram-negative (CRG) resistant resistant across eight geographically diverse and populated luminous-ranglades, Brazil, Egypt, India, Kenya, Mexico, Pakistan and South Africa. India 7.8% of measures are 6.9% on average in all eight countries.
The study was carried out for the purpose of determining barriers along the treatment route from the initial presentation in medical facilities to laboratory diagnostic testing for antibiotic access.
Two key parameters
Scientists have defined and estimated two key parameters – the need for treatment or the total number of resistant bacterial infections; The number of individuals potentially initiated in appropriate treatment, specifically focused on CRGN infections. Scientists used the study of Lancet’s “Global Stress of Antimicrobial Resistance” (GRAM) and IQVIA data for 2019 to reach numbers.
“We looked at three aspects,” explains Jennifer Cohn, director of the Global Gardp approach and the head of the study. “It was: To evaluate access to an antibiotic gap; create better data that would be necessary to better define a cascade of care; and look at strong programs or innovations that have allowed better antibiotics management in nations.” While the study focused only on eight countries, including India, she said there was a good reason to believe that the findings of this study also apply to other lms.
“We all know that top antibiotics are considerably overused and abused in countries like India, which contributes to resistance to these drugs. However, this document reminds us of an equally alarming problem-the access to these same antibiotics,” trust amr.
“In 2019, India had nearly 10 lakh carbapene resistant gram -negative infections, but less than 1 Lakh patients received adequate treatment. Modeling suggests that we have approximately 3.5 lakh deaths as a result of these infections.
“In order to deal with this double crisis, we must act on both fronts: to maintain existing antibiotics through responsible use and ensure access to those who really need them,” Dr. Ghafur. In the post, which is the author of Anant Misra et al, the recommendation has a regulatory railing that not only controls the use of antibiotics, but also makes sure that the access gap is overwhelmed by nations and institutions. They also call for further research to better understand obstacles to access to care, diagnoses and appropriate treatment.
Published – May 1 2025 04:47 IS
